GO:0043616 keratinocyte proliferation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043616 keratinocyte proliferation describes the multiplication of keratinocytes, the keratin-synthesizing cells of the epidermis, leading to expansion of the epidermal cell population.
• Keratinocyte proliferation is controlled by a balance of growth factors, cytokines, mechanical cues and cell-cycle regulators, and its dysregulation underlies psoriasis, chronic wounds and skin cancer.
• Key molecular drivers include KGF, OPN, PA2G4, RUNX1 and cPLA2-dependent arachidonic acid metabolism, while lncRNA H19 and miR-17-5p provide additional regulatory layers.
• Pharmacological and natural compounds such as albendazole and dexamethasone can negatively or positively regulate keratinocyte proliferation, offering experimental entry points.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate genes in keratinocyte proliferation.
• Studying GO:0043616 requires combining proliferation assays, cell-cycle analysis, transcriptomics and imaging to capture the full epidermal expansion program.
Description
Keratinocyte proliferation (GO:0043616) is the biological process by which keratinocytes, the predominant cell type of the epidermis, multiply and expand their population. These cells synthesize keratin and undergo a characteristic differentiation program as they move from the basal layer toward the cornified layer, making controlled proliferation essential for skin homeostasis and repair. Because the epidermis is continuously renewed, keratinocyte proliferation must be tightly balanced with differentiation and cell death; disruption of this balance is a hallmark of hyperproliferative skin diseases such as psoriasis and of impaired healing in chronic wounds. Researchers study GO:0043616 to understand epidermal development, to identify therapeutic targets for inflammatory skin diseases, and to evaluate biomaterials for dental and dermal implants that require keratinocyte colonization. The process is regulated by a complex network of growth factors, cytokines, mechanical signals and non-coding RNAs, and recent work has begun to define the specific molecular effectors that drive or restrain keratinocyte multiplication.
keratinocyte proliferation At A Glance
| GO ID | GO:0043616 |
|---|---|
| GO term | keratinocyte proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Multiplication of keratinocytes leading to expansion of the epidermal cell population |
| Cell type | Keratinocytes, epidermal cells that synthesize keratin |
| Tissue context | Epidermis, including basal and suprabasal layers |
| Related processes | Keratinocyte differentiation, migration, wound healing and skin inflammation |
| Disease relevance | Psoriasis, chronic wounds, hyperproliferative skin disorders |
What Is GO:0043616?
GO:0043616 keratinocyte proliferation is defined in QuickGO as the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population. Keratinocytes are epidermal cells that synthesize keratin and undergo a characteristic change as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. In practical terms, the term covers the mitotic and cell-cycle events that increase keratinocyte number, as distinct from keratinocyte differentiation or migration, although these processes are functionally coupled in the epidermis.
Why Is keratinocyte proliferation Important in Cell Biology?
Keratinocyte proliferation is central to skin biology because it supplies the cells that maintain the epidermal barrier and repair wounds, and because its dysregulation drives common and burdensome diseases. In psoriasis, excessive keratinocyte proliferation contributes to epidermal thickening and scaling, and molecules such as PA2G4 and osteopontin have been shown to promote this proliferative phenotype. In chronic wounds, impaired keratinocyte proliferation and migration delay re-epithelialization, and lncRNA H19 has been reported to inhibit these processes via the miR-17-5p/RUNX1 axis. Understanding GO:0043616 therefore has direct implications for dermatology, wound care, implantology and cancer biology, and it provides a tractable experimental system for testing gene function with CRISPR-based models.
• Maintains epidermal homeostasis by balancing proliferation with differentiation.
• Drives re-epithelialization and wound closure after skin injury.
• Is hyperactivated in psoriasis, contributing to epidermal hyperplasia.
• Is impaired in chronic wounds, where non-coding RNAs can suppress proliferation.
• Is modulated by growth factors such as KGF released from mast cells.
• Is influenced by mechanical and metabolic signals, including arachidonic acid metabolism.
• Can be negatively regulated by compounds such as albendazole.
• Is relevant to implant surfaces that must support keratinocyte colonization.
• Provides a model for studying cell-cycle control and G0/G1 arrest.
• Offers CRISPR-tractable targets for therapeutic intervention.
What Happens During keratinocyte proliferation?
Initiation by growth factors and cytokines
In simple terms: Keratinocytes start dividing when they receive growth signals from nearby cells.
Keratinocyte proliferation is initiated by extracellular cues such as keratinocyte growth factor (KGF), which can be triggered in mast cells by dexamethasone and then act on keratinocytes to promote their proliferation. Other soluble mediators, including osteopontin, have been shown to promote keratinocyte proliferation in psoriasis. These signals converge on receptors and intracellular pathways that license cells to enter the cell cycle.
Cell-cycle entry and G0/G1 progression
In simple terms: Once signaled, keratinocytes move from a resting state into the active division cycle.
A key step in keratinocyte proliferation is progression through the G0/G1 checkpoint of the cell cycle. Osteopontin has been reported to promote keratinocyte proliferation by modulating G0/G1 cell cycle arrest in psoriasis, indicating that release from arrest is a controlled node in this process. General regulation of keratinocyte proliferation involves cell-cycle machinery that determines whether cells commit to DNA synthesis and division.
Mechanical and metabolic modulation
In simple terms: Physical forces and lipid signals can also push keratinocytes to divide.
Mechano-induced arachidonic acid metabolism promotes keratinocyte proliferation through regulation of cPLA2 activity, linking mechanical cues to lipid signaling and proliferative output. This demonstrates that GO:0043616 is not only growth-factor driven but also responsive to the physical and metabolic environment of the epidermis.
Non-coding RNA and transcriptional control
In simple terms: Small and long RNAs can put brakes on keratinocyte division.
The lncRNA H19 inhibits keratinocyte cell proliferation and migration by targeting the miR-17-5p/RUNX1 axis in chronic wounds, showing that non-coding RNAs can suppress GO:0043616. Conversely, proliferation-associated protein 2G4 (PA2G4) promotes keratinocyte proliferation and survival in psoriasis, illustrating positive transcriptional and post-transcriptional regulation. Together these layers fine-tune the rate of keratinocyte multiplication.
Pharmacological and environmental regulation
In simple terms: Drugs and external agents can speed up or slow down keratinocyte division.
Albendazole negatively regulates keratinocyte proliferation, providing a chemical tool to reduce this process. Dexamethasone, by contrast, promotes keratinocyte proliferation indirectly by triggering KGF in mast cells. These examples show that GO:0043616 can be modulated by pharmacological and microenvironmental inputs, which is useful for experimental control.
Key Genes Involved in GO:0043616 keratinocyte proliferation
The following genes and proteins have been experimentally linked to keratinocyte proliferation (GO:0043616) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KGF (FGF7) | Growth factor that promotes keratinocyte proliferation | Mediates dexamethasone-induced proliferation via mast cells |
| OPN (SPP1) | Promotes keratinocyte proliferation | Linked to G0/G1 cell cycle arrest in psoriasis |
| PA2G4 | Promotes keratinocyte proliferation and survival | Implicated in psoriasis pathogenesis |
| RUNX1 | Transcription factor targeted by miR-17-5p | Involved in H19-mediated inhibition of proliferation in chronic wounds |
| H19 | Long non-coding RNA that inhibits proliferation | Targets miR-17-5p/RUNX1 axis in chronic wounds |
| miR-17-5p | MicroRNA regulating RUNX1 | Mediates H19 effects on keratinocyte proliferation |
| cPLA2 | Enzyme in arachidonic acid metabolism | Mechano-induced proliferation via lipid signaling |
| KRT (keratins) | Structural proteins of keratinocytes | Markers of keratinocyte identity in proliferation studies |
| EGFR | Growth factor receptor signaling | General regulator of keratinocyte proliferation |
| Cyclin D1 (CCND1) | Cell-cycle regulator | Controls G1 progression in keratinocytes |
| CDK4/6 | Cell-cycle kinases | Drive G1/S transition in proliferating keratinocytes |
| TP53 | Tumor suppressor | Restrains aberrant keratinocyte proliferation |
| TGF-beta | Growth factor with context-dependent effects | Regulates keratinocyte proliferation balance |
| IL-6 | Cytokine | Modulates keratinocyte proliferation in inflammation |
| TNF-alpha | Cytokine | Influences keratinocyte proliferation in skin inflammation |
| Integrin alpha-6 | Hemidesmosome component | Supports keratinocyte adhesion and proliferation on implant surfaces |
| Laminin-5 | Extracellular matrix protein | Facilitates keratinocyte proliferation and hemidesmosome formation |
How Is keratinocyte proliferation Regulated?
Keratinocyte proliferation is regulated at multiple levels. Growth factors such as KGF promote proliferation, and dexamethasone can indirectly stimulate this pathway by inducing KGF in mast cells. Osteopontin modulates G0/G1 cell cycle arrest to promote proliferation in psoriasis. Mechanical cues regulate arachidonic acid metabolism through cPLA2 activity, linking physical forces to proliferative signaling. Non-coding RNAs add another layer: lncRNA H19 inhibits proliferation by targeting the miR-17-5p/RUNX1 axis in chronic wounds. PA2G4 promotes keratinocyte proliferation and survival in psoriasis, while albendazole negatively regulates proliferation. These diverse inputs converge on cell-cycle control and survival pathways that determine the rate of epidermal expansion.
keratinocyte proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PA2G4 | Psoriasis | Keratinocyte overexpression and knockout in psoriasis-like models |
| SPP1 (OPN) | Psoriasis | Knockout and point-mutation models to test G0/G1 arrest |
| H19 | Chronic wounds | Overexpression and knockout in wound healing assays |
| RUNX1 | Chronic wounds | Knock-in and knockout to test miR-17-5p targeting |
| cPLA2 | Mechano-induced proliferation | Point-mutation models to dissect lipid signaling |
Psoriasis
Psoriasis is characterized by hyperproliferation of keratinocytes and epidermal thickening. PA2G4 promotes keratinocyte proliferation and survival in psoriasis, and osteopontin promotes keratinocyte proliferation by modulating G0/G1 cell cycle arrest, highlighting these molecules as potential therapeutic targets.
Chronic wounds
In chronic wounds, impaired keratinocyte proliferation and migration contribute to delayed healing. The lncRNA H19 inhibits keratinocyte cell proliferation and migration by targeting the miR-17-5p/RUNX1 axis, suggesting that modulating this axis could improve re-epithelialization.
Implant integration
Keratinocyte proliferation and hemidesmosome formation on dental implant surfaces are critical for soft tissue integration. In vitro studies have evaluated surfaces for dental implants to promote keratinocyte proliferation and hemidesmosome formation, linking GO:0043616 to implantology.
Pharmacological modulation
Albendazole negatively regulates keratinocyte proliferation, indicating that pharmacological control of this process is feasible and may be relevant for hyperproliferative skin conditions. Dexamethasone promotes keratinocyte proliferation via KGF from mast cells, illustrating context-dependent drug effects.
From keratinocyte proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene drive keratinocyte proliferation? | CRISPR knockout in primary keratinocytes or HaCaT cells |
| Does a specific mutation alter proliferation? | Point-mutation knock-in in keratinocyte lines |
| Does overexpression of a factor increase proliferation? | Overexpression models in keratinocytes |
| How does a gene affect G0/G1 progression? | Knockout combined with cell-cycle analysis |
| Does a lncRNA regulate proliferation via a miRNA axis? | Knockout and overexpression of H19 and miR-17-5p |
| Can a drug modulate keratinocyte proliferation? | Pharmacological treatment with albendazole or dexamethasone in vitro |
How to Study the keratinocyte proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and proliferation | Quantifying keratinocyte proliferation |
| MTT assay | Metabolic activity and cell number | Drug effects on keratinocyte proliferation |
| Flow cytometry | Cell-cycle distribution | G0/G1 arrest analysis |
| RNA-seq | Global transcriptome changes | Identifying proliferation-associated genes |
| qPCR | Expression of lncRNAs and miRNAs | Validating H19/miR-17-5p axis |
| Immunofluorescence | Protein localization and hemidesmosomes | Implant surface studies |
| Western blot | Protein expression and signaling | Pathway analysis in proliferation |
| CRISPR screening | Gene function at scale | Identifying novel regulators of proliferation |
Proliferation assays
Standard proliferation assays such as MTT, BrdU or EdU incorporation measure the expansion of keratinocyte populations and are used to quantify GO:0043616 under different conditions.
Cell-cycle analysis
Flow cytometry and cell-cycle markers can determine whether keratinocytes are arrested at G0/G1 or progressing through the cycle, as shown for osteopontin-mediated proliferation.
Transcriptomics and non-coding RNA profiling
RNA-seq and targeted analysis of lncRNAs and miRNAs, such as H19 and miR-17-5p, reveal regulatory layers controlling keratinocyte proliferation.
Imaging and hemidesmosome assessment
Immunofluorescence and microscopy can visualize keratinocyte proliferation markers and hemidesmosome formation on surfaces such as dental implants.
How CRISPR Can Be Used to Study GO:0043616 keratinocyte proliferation
Knockout
CRISPR knockout of candidate genes such as PA2G4, SPP1 or H19 can test whether they are required for keratinocyte proliferation, using assays like EdU incorporation and cell-cycle analysis.
Point Mutation
Point-mutation models can dissect specific residues in enzymes such as cPLA2 to determine how catalytic activity contributes to mechano-induced keratinocyte proliferation.
Knock-in
Knock-in of tagged or mutant alleles allows tracking of proteins like RUNX1 and assessment of their role in the miR-17-5p/H19 axis during proliferation.
Overexpression
Overexpression of factors such as KGF or H19 can test sufficiency for promoting or inhibiting keratinocyte proliferation in vitro and in vivo.
How EDITGENE Supports keratinocyte proliferation Research
Researchers studying keratinocyte proliferation-related genes often need to determine whether a candidate gene is causally involved in the expansion of keratinocyte populations, and CRISPR-based models provide a direct way to test this. By combining knockout, point-mutation, knock-in and overexpression approaches with proliferation and cell-cycle readouts, it is possible to move from correlation to causation in the context of GO:0043616.
Contact EDITGENE today to design your custom CRISPR model for keratinocyte proliferation research.
Frequently Asked Questions About keratinocyte proliferation
What is GO:0043616 keratinocyte proliferation?
GO:0043616 is the biological process of keratinocyte multiplication, resulting in expansion of the epidermal cell population.
What genes are involved in keratinocyte proliferation?
Genes such as KGF, SPP1 (osteopontin), PA2G4, RUNX1, H19, miR-17-5p and cPLA2 have been linked to keratinocyte proliferation.
How is keratinocyte proliferation regulated?
It is regulated by growth factors, cytokines, mechanical cues, non-coding RNAs and cell-cycle checkpoints.
What diseases involve abnormal keratinocyte proliferation?
Psoriasis and chronic wounds are prominent examples where keratinocyte proliferation is dysregulated.
Can CRISPR be used to study keratinocyte proliferation?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models can test causal roles of genes in keratinocyte proliferation.
What assays measure keratinocyte proliferation?
EdU/BrdU incorporation, MTT assays and flow cytometry are commonly used to measure keratinocyte proliferation.
Does dexamethasone affect keratinocyte proliferation?
Dexamethasone can promote keratinocyte proliferation by triggering KGF in mast cells.
What is the role of H19 in keratinocyte proliferation?
H19 inhibits keratinocyte proliferation and migration by targeting the miR-17-5p/RUNX1 axis in chronic wounds.
How does osteopontin affect keratinocyte proliferation?
Osteopontin promotes keratinocyte proliferation by modulating G0/G1 cell cycle arrest in psoriasis.
Why is keratinocyte proliferation important for implants?
Keratinocyte proliferation and hemidesmosome formation are needed for soft tissue integration on dental implant surfaces.
Conclusion
GO:0043616 keratinocyte proliferation is a central biological process that sustains epidermal renewal and repair, and its dysregulation contributes to psoriasis, chronic wounds and other skin disorders. The process is controlled by a network of growth factors, cytokines, mechanical signals and non-coding RNAs, with key nodes including KGF, osteopontin, PA2G4, RUNX1, H19 and cPLA2. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide powerful tools to dissect these mechanisms and to identify therapeutic targets, and EDITGENE offers end-to-end services to support such studies.
References
- 1. Di Fusco D et al.. 2020. Albendazole negatively regulates keratinocyte proliferation.. Clin Sci (Lond) 134(7):907-920 PMID: 32236445
- 2. Gniadecki R. 1998. Regulation of keratinocyte proliferation.. Gen Pharmacol 30(5):619-22 PMID: 9559309
- 3. Raunegger T et al.. 2026. Proliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis.. Br J Dermatol 195(3):461-472 PMID: 42008715
- 4. Gargallo-Albiol J et al.. 2023. Keratinocyte Proliferation and Hemidesmosome Formation on Surfaces for Dental Implants: In Vitro Study.. Int J Oral Maxillofac Implants 38(3):496-502 PMID: 37279216
- 5. Ji W et al.. 2024. LncRNA H19 Inhibits Keratinocyte Cell Proliferation and Migration by Targeting miR-17-5p/RUNX1 Axis in Chronic Wounds.. J Burn Care Res 45(2):366-372 PMID: 37742288
- 6. Cho KA et al.. 2019. Dexamethasone Promotes Keratinocyte Proliferation by Triggering Keratinocyte Growth Factor in Mast Cells.. Int Arch Allergy Immunol 179(1):53-61 PMID: 30909282
- 7. Shan S et al.. 2024. Mechano-induced arachidonic acid metabolism promotes keratinocyte proliferation through cPLA2 activity regulation.. FASEB J 38(23):e70226 PMID: 39636236
- 8. Tang S et al.. 2025. Osteopontin promotes keratinocyte proliferation by G0/G1 cell cycle arrest in psoriasis.. Arch Dermatol Res 317(1):519 PMID: 40035859
